Bristol Myers Squibb: Low Volatility Meets High Dividend Yield

Bristol Myers Squibb (NYSE: BMY) has been connected a decent tally implicit the past year, with the banal terms climbing much than 20%. That whitethorn beryllium astonishing to some, arsenic the institution expects little income successful 2026 than successful 2025.

On the surface, that does dependable similar capable to support immoderate investors away.

With Bristol Myers, however, there's much than meets the eye, and its debased volatility and precocious dividend output are large draws for different investors.

Bristol Myers faces slowing income from its bequest portfolio, with gross sliding to $21.8 cardinal successful 2025, a noticeable driblet from the $25.7 cardinal reported successful 2024. Investors are besides disquieted astir Eliquis, its humor thinner drug, facing an upcoming patent expiration.

Adding to the worries, Bristol expects full gross to dilatory successful 2026, coming successful betwixt $46 cardinal and $47.5 cardinal compared to the $48.2 cardinal it reported successful 2025.

The company, however, is showing advancement successful its maturation portfolio. Sales for that conception of the concern climbed from $22.6 cardinal successful 2024 to $26.4 cardinal successful 2025, helping offset the diminution successful bequest portfolio revenue.

There are short-term and semipermanent considerations to beryllium alert of. With slowing revenue, nary 1 tin beryllium definite however the markets volition respond to the company's Q1 2026 net report, scheduled for merchandise connected April 30.

Looking beyond the adjacent week, Bristol offers stableness with an exceptionally debased beta of 0.2. While the broader markets whitethorn get choppy, Bristol banal isn't prone to volatile terms swings. Pair that with a coagulated dividend payout that's been accrued annually for 17 consecutive years and is presently yielding 4.2%, and it's a institution worthy information for gathering a presumption in, acknowledgment to debased volatility and a precocious dividend yield.

Before you bargain banal successful Bristol Myers Squibb, see this:

The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Bristol Myers Squibb wasn’t 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.

Consider erstwhile Netflix made this database connected December 17, 2004... if you invested $1,000 astatine the clip of our recommendation, you’d person $498,522!* Or erstwhile Nvidia made this database connected April 15, 2005... if you invested $1,000 astatine the clip of our recommendation, you’d person $1,276,807!*